Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

Exclusion Criteria

• •Alanine aminotransferase (ALT) \>1.5 x upper limit of normal range (ULN)
• •Bilirubin \>1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent \[%\]).
• •Current or chronic history of liver disease, or known hepatic or biliary abnormalities
• •QT interval corrected for heart rate according to Fridericia's formula (QTcF) \> 450 millisecond (msec).
• •Systolic blood pressure is \>=140 millimeter of mercury (mmHg) at Screening;
• •Diastolic blood pressure is \>=90 mmHg at Screening;
• •Heart rate is \>100 beats/min at Screening.
• •estimated glomerular filtration rate (eGFR) \<=80 milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2) (calculated using the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula) at Screening.
• •Fasting triglyceride level \>300 milligram per deciliter (mg/dL) at Screening.
• •History of significant cardiovascular or pulmonary dysfunction prior to Screening.
• •History of thyroid dysfunction or an abnormal (i.e., outside the normal reference range) thyroid function test assessed by thyroid stimulating hormone at Screening.
• •History of gastrointestinal surgery that could influence gastric emptying (e.g., gastrectomy, gastric bypass).
• •History of pancreatitis.
• •Personal or family history of multiple endocrine neoplasia type 2.
• •Personal or family history of medullary carcinoma of the thyroid.
• •Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days.
• •History of regular alcohol consumption within 6 months of the study.
• •Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 3 months prior to screening.
• •History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy.
• •Subject has previously received any GLP-1 mimetic compound (eg., exenatide, liraglutide, lixisenatide, dulaglutide).
• •Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment.
• •A positive pre-study drug/alcohol screen.
• •A positive test for human immunodeficiency virus (HIV) antibody.
• •Subject has donated blood in excess of 500 mL within 56 days prior to dosing or intention of donating in the month after completing the study.
• •The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
• •Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day